Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial offers hope for rare liver disease

NCT ID NCT05896137

Summary

This study is testing an experimental drug called CS0159 for people with Primary Sclerosing Cholangitis (PSC), a rare disease that scars the bile ducts in the liver. The main goal is to see if the drug is safe and if it can lower a key liver enzyme (ALP) over 12 weeks. The trial will involve about 50 adult patients in China, who will be randomly assigned to receive either the drug or a placebo for the first part, followed by a longer open-label period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Friendship Hospital, Captail Medcial University

    Beijing, Beijing Municipality, 100050, China

  • Beijing YouAn Hostital, Captial Medical University

    Beijing, Beijing Municipality, 100069, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200120, China

  • Shaoyifu Hospital of Zhejiang University Medical

    Hangzhou, Zhejiang, 310000, China

  • The First Affiliated Hospital of USTC Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • The Seconed Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • Wuhan Union Hospital of China

    Wuhan, Hubei, 430022, China

Conditions

Explore the condition pages connected to this study.